1Aronson D,Rayfield EJ,Chesebro JH.Mechanisms determiningcourse and outcome of diabetes patients who have had acute myocardial infarction[].Annals of Internal Medicine.1997
2Goldberg RB,Mellies MJ,Sacks FM,et al.Cardiovascular events andtheir reduction with pravastatin in diabetic and glucose-intolerantmyocrdial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial[].Circulation.1998
3Turner RC,Millns H,Neil H,et al.For the united kingdom prospective diabetes study group.Risk factors for coronary artery disease innon-insulin dependent diabetes mellitus:United kingdom prospectivediabetes study (UKPDS: 23)[].British Medical Journal.1998
4Koskinen P,Manttari M,Manninen V,et al.Coronary heart diseaseincidence in NIDDM patients in the helsinki heart study[].Diabetes Care.1992
5The DCCT Research group.Lipid and lipoprotein levels in patientswith IDDM: Diabetes control and complication trial experience[].Diabetes Care.1992
6Jeppesen J,Hem HO,Suadicani P,et BI.Trislyceride concentrationand ischemic heart disease, an eight-year follow-up in the copenhagen male study[].Circulation.1998
7PysrilaK,Pedersen TR,Kjekshus J,et al.The scandinavian simvastatin survival study (4S) group: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin survivalstudy (4S)[].Diabetes Care.1997
8UK Prospective Diabetes Study Group.Tight blood pressure controland risk of macrovascular complication type 2 diabetes: UKPDS38[].British Medical Journal.1998
